Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

Study:

A Multicenter, Phase IV Study to Evaluate the Ability of Definity® Enhanced Versus Unenhanced Echocardiography to Improve the Accuracy and Reproducibility of Left Ventricular Ejection Fraction When Compared to Cardiac Magnetic Resonance Imaging

Rationale:

n/a

Purpose:

The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when compared to magnetic resonance imaging (MRI).

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Ventricular Ejection Fraction Drug: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension Phase 4

Verified by Lantheus Medical Imaging May, 2011

Sponsored by: Lantheus Medical Imaging
Information provided by: Lantheus Medical Imaging
ClinicalTrials.gov identifier: NCT00401687

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Veronica Lee, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.